In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenetic Biosciences Inc.

www.xeneticbio.com

Latest From Xenetic Biosciences Inc.

Pipeline Watch: Phase III Progress With Anacetrapib, ALKS 3831 And LentiGlobin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Top-Line Ozanimod, Romosozumab, Cariprazine Phase III Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Bioverativ Fills Gap In Pipeline With $400m True North Buy

Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments. The deal gives Bioverativ a clinical asset, helping to fill the gap between preclinical programs and commercial products in its R&D pipeline.

Deals Business Strategies

Shire Discontinues Development Of Once-Weekly SHP656 For Hemophilia A

Shire's cash-strapped partner Xenetic, whose technology enabled the long-acting Factor VIII, said on May 22 that SHP656 could not achieve once-weekly dosing in a Phase I/II clinical trial. The market for such a product may be limited anyway given current competition and payer preferences.

Research & Development Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Lipoxen Technologies Ltd.
  • Lipoxen PLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Xenetic Biosciences Inc.
  • Senior Management
  • Jeffrey F Eisenberg, CEO
    James F Parslow, CFO
    Curtis Lockshin, PhD, CSO
  • Contact Info
  • Xenetic Biosciences Inc.
    Phone: (44)(781) 778-7720
    40 Speen St.
    Ste. 102
    Framingham, MA 01701
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register